Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $11.1250.

A number of equities research analysts have commented on the stock. Noble Financial assumed coverage on shares of Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $2.87 on Friday. Cardiff Oncology has a 52-week low of $1.90 and a 52-week high of $4.99. The business’s 50 day moving average price is $2.49 and its two-hundred day moving average price is $2.58. The firm has a market cap of $193.32 million, a PE ratio of -3.63 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.12 million. Research analysts predict that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors have recently modified their holdings of the company. Baader Bank Aktiengesellschaft purchased a new position in shares of Cardiff Oncology in the 2nd quarter worth approximately $32,000. Belpointe Asset Management LLC bought a new stake in Cardiff Oncology during the first quarter worth $37,000. Jeppson Wealth Management LLC bought a new stake in Cardiff Oncology during the third quarter worth $25,000. Brooklyn Investment Group bought a new position in Cardiff Oncology in the 3rd quarter valued at $26,000. Finally, Integrity Alliance LLC. bought a new position in Cardiff Oncology in the 2nd quarter valued at $41,000. 16.29% of the stock is owned by institutional investors and hedge funds.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.